[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review

D Jeremic, L Jiménez-Díaz, JD Navarro-López - Ageing research reviews, 2021 - Elsevier
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

[HTML][HTML] Hypoxia and brain aging: Neurodegeneration or neuroprotection?

J Burtscher, RT Mallet, M Burtscher, GP Millet - Ageing research reviews, 2021 - Elsevier
The absolute reliance of the mammalian brain on oxygen to generate ATP renders it acutely
vulnerable to hypoxia, whether at high altitude or in clinical settings of anemia or pulmonary …

[HTML][HTML] Antioxidants in Alzheimer's disease: Current therapeutic significance and future prospects

P Pritam, R Deka, A Bhardwaj, R Srivastava, D Kumar… - Biology, 2022 - mdpi.com
Simple Summary Alzheimer's disease (AD) is the most common neurodegenerative disease,
intensifying impairments in cognition, behavior, and memory. Histopathological AD …

The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer's disease

I Vecchio, L Sorrentino, A Paoletti… - Journal of Central …, 2021 - journals.sagepub.com
Alzheimer's disease (AD) is a chronic disabling disease that affects the central nervous
system. The main consequences of AD include the decline of cognitive functions and …

Intranasal delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for Alzheimer's disease therapy

X Yang, W Yang, X Xia, T Lei, Z Yang, W Jia, Y Zhou… - Small, 2022 - Wiley Online Library
Abstract Alzheimer's disease (AD), as a progressive and irreversible brain disorder, remains
the most universal neurodegenerative disease. No effective therapeutic methods are …

Blood-brain barrier dysfunction in normal aging and neurodegeneration: mechanisms, impact, and treatments

AV Andjelkovic, M Situ, AF Citalan-Madrid… - Stroke, 2023 - Am Heart Assoc
Cerebral endothelial cells and their linking tight junctions form a unique, dynamic and multi-
functional interface, the blood-brain barrier (BBB). The endothelium is regulated by …

[HTML][HTML] Mechanisms of ferroptosis in Alzheimer's disease and therapeutic effects of natural plant products: a review

D Zhao, K Yang, H Guo, J Zeng, S Wang, H Xu… - Biomedicine & …, 2023 - Elsevier
Neurodegenerative diseases, such as Alzheimer's disease (AD), are characterized by
massive loss of specific neurons. It is a progressive disabling, severe and fatal complex …

[HTML][HTML] Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases

L Qian, Y Zhu, C Deng, Z Liang, J Chen… - … and Targeted Therapy, 2024 - nature.com
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family (PGC-1s),
consisting of three members encompassing PGC-1α, PGC-1β, and PGC-1-related …

[HTML][HTML] Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives

L La Barbera, E Mauri, M D'Amelio… - Frontiers in neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD), the most common form of dementia, is a progressive and
multifactorial neurodegenerative disorder whose primary causes are mostly unknown. Due …

[HTML][HTML] Small-molecule theranostics in Alzheimer's disease

Á Sarabia-Vallejo, P López-Alvarado… - European Journal of …, 2023 - Elsevier
Alzheimer's Disease (AD) remains one of the most challenging health-related issues for our
society. It is becoming increasingly prevalent, especially in developed countries, due to the …